Christopher Frampton

Christopher Frampton is a notable inventor based in Stowmarket, GB. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on therapeutic cocrystals and crystalline salts. With a total of 12 patents to his name, Frampton's inventions are paving the way for advancements in drug formulation and delivery.

Latest Patents

Frampton's latest patents include the development of therapeutic cocrystals of a specific benzamide compound, identified as 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide. These cocrystals have various therapeutic uses and are designed to enhance the efficacy of the benzamide compound. The invention also details several cocrystal forms, including those with fumaric acid, maleic acid, malonic acid, L-tartaric acid hydrate, and gentisic acid. Additionally, Frampton has worked on crystalline tranilast salts, focusing on their preparation, characterization, and pharmaceutical applications.

Career Highlights

Throughout his career, Christopher Frampton has been associated with companies such as Nuformix Limited and Nuformix Technologies Limited. His work has been instrumental in advancing pharmaceutical formulations that can lead to improved treatment options for patients.

Collaborations

Frampton has collaborated with notable colleagues, including Joanne Holland and Alan Chorlton, contributing to a dynamic research environment that fosters innovation and development in pharmaceutical sciences.

Conclusion

Christopher Frampton's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of new therapeutic options, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.